{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:57:46Z","timestamp":1782932266606,"version":"3.54.5"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00296-018-4202-2","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T04:53:32Z","timestamp":1541739212000},"page":"417-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bulgarian rheumatology: science and practice in a cost-constrained environment"],"prefix":"10.1007","volume":"39","author":[{"given":"Tsvetoslav","family":"Georgiev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumen","family":"Stoilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"issue":"2","key":"4202_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4081\/reumatismo.2014.783","volume":"66","author":"L Sinigaglia","year":"2014","unstructured":"Sinigaglia L (2014) Metabolic bone diseases: an overview. Reumatismo 66(2):109\u2013111. https:\/\/doi.org\/10.4081\/reumatismo.2014.783","journal-title":"Reumatismo"},{"key":"4202_CR2","doi-asserted-by":"crossref","DOI":"10.1201\/b16350","volume-title":"Rheumatology: a color handbook","author":"TR Mikuls","year":"2013","unstructured":"Mikuls TR et al (2013) Rheumatology: a color handbook. CRC Press, Boca Raton"},{"issue":"4","key":"4202_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.berh.2008.07.001","volume":"22","author":"A Chopra","year":"2008","unstructured":"Chopra A, Abdel-Nasser A (2008) Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol 22(4):583\u2013604. https:\/\/doi.org\/10.1016\/j.berh.2008.07.001","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"4202_CR4","doi-asserted-by":"publisher","first-page":"SR1","DOI":"10.12659\/MSM.881697","volume":"17","author":"E Orlewska","year":"2011","unstructured":"Orlewska E, Ancuta I, Anic B, Codrenau C, Damjanov N, Djukic P, Ionescu R, Marinchev L, Nasonov EL, Peets T, Praprotnik S (2011) Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 17(4):SR1","journal-title":"Med Sci Monit"},{"key":"4202_CR5","unstructured":"National Center of Public Health and Analyses of Bulgaria (2018) Hospitalized patients (discharged and deceased) in hospitals by classes of ICD-10 in 2016 (Internet). http:\/\/ncpha.government.bg\/files\/nczi\/zdr.statistika\/health_BB_6.pdf . Accessed 25 July 2018"},{"key":"4202_CR6","first-page":"13","volume-title":"History of rheumatology in Bulgaria [\u0420\u0430\u0437\u0432\u0438\u0442\u0438\u0435 \u043d\u0430 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f\u0442\u0430 \u0432 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f. \u0412: \u0418\u0441\u0442\u043e\u0440\u0438\u044f \u043d\u0430 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f\u0442\u0430 \u0432 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f]","author":"Z Kolarov","year":"2014","unstructured":"Kolarov Z, Monov S (2014) Development of Rheumatology in Bulgaria. In: History of rheumatology in Bulgaria [\u0420\u0430\u0437\u0432\u0438\u0442\u0438\u0435 \u043d\u0430 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f\u0442\u0430 \u0432 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f. \u0412: \u0418\u0441\u0442\u043e\u0440\u0438\u044f \u043d\u0430 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f\u0442\u0430 \u0432 \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f]. Central Medical Library of Medical University-Sofia, Sofia, pp\u00a013\u201317"},{"issue":"2\u20133","key":"4202_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.healthpol.2010.12.001","volume":"102","author":"E Atanasova","year":"2011","unstructured":"Atanasova E, Pavlova M, Velickovski R, Nikov B, Moutafova E, Groot W (2011) What have 10 years of health insurance reforms brought about in Bulgaria? Re-appraising the Health Insurance Act of 1998. Health Policy 102(2\u20133):263\u2013269","journal-title":"Health Policy"},{"issue":"9","key":"4202_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/rheumatology\/ket008","volume":"52","author":"T Cheng","year":"2013","unstructured":"Cheng T, Guoyou Z (2013) Worldwide research productivity in the field of rheumatology from 1996 to 2010: a bibliometric analysis. Rheumatology 52(9):1630\u20131634. https:\/\/doi.org\/10.1093\/rheumatology\/ket008","journal-title":"Rheumatology"},{"issue":"11","key":"4202_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"issue":"7617","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/bmj.39308.342639.AD","volume":"335","author":"A Woywodt","year":"2007","unstructured":"Woywodt A, Matteson EL (2007) Head to head: should eponyms be abandoned? Yes. BMJ 335(7617):424. https:\/\/doi.org\/10.1136\/bmj.39308.342639.AD","journal-title":"BMJ"},{"issue":"11","key":"4202_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/rheumatology\/kel259","volume":"45","author":"EL Matteson","year":"2006","unstructured":"Matteson EL, Woywodt A (2006) Eponymophilia in rheumatology. Rheumatology 45(11):1328\u20131330. https:\/\/doi.org\/10.1093\/rheumatology\/kel259","journal-title":"Rheumatology"},{"issue":"9963","key":"4202_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"II Abubakar","year":"2015","unstructured":"Abubakar II, Tillmann T, Banerjee A (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117\u2013171","journal-title":"Lancet"},{"key":"4202_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-908517-22-7","volume-title":"Pocket reference to early rheumatoid arthritis","author":"P Emery","year":"2011","unstructured":"Emery P (2011) Pocket reference to early rheumatoid arthritis. Springer, Berlin"},{"key":"4202_CR14","unstructured":"Kobelt G, Kasteng F (2009) Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA)\u00a0(Internet).\u00a0 http:\/\/www.comparatorreports.se\/Access%20to%20RA%20Treatments%20October%202009.pdf . Accessed 14 Oct 2018"},{"issue":"3","key":"4202_CR15","first-page":"52","volume":"16","author":"P Solakov","year":"1977","unstructured":"Solakov P, Khristova M (1977) Rheumatoid arthritis among the rural population of southern Bulgaria (transitory morbidity established using the Rome and New York diagnostic criteria). Vutreshni Boles 16(3):52\u201356","journal-title":"Vutreshni Boles"},{"issue":"9","key":"4202_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"4202_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","volume":"74","author":"P Verschueren","year":"2015","unstructured":"Verschueren P, De Cock D, Corluy L et al (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis 74:27\u201334. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205489","journal-title":"Ann Rheum Dis"},{"key":"4202_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O\u2019Dell","year":"2013","unstructured":"O\u2019Dell JR, Mikuls TR, Taylor TH et al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369:307\u2013318. https:\/\/doi.org\/10.1056\/NEJMoa1303006","journal-title":"N Engl J Med"},{"issue":"6","key":"4202_CR19","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"4202_CR20","unstructured":"Bulgarian Rheumatology Society (2018) National consensus for the treatment of rheumatoid arthritis with biologic agents [\u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u0435\u043d \u043a\u043e\u043d\u0441\u0435\u043d\u0441\u0443\u0441 \u0437\u0430 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u0435\u043d \u0430\u0440\u0442\u0440\u0438\u0442 \u0441 \u0431\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u043d\u0438 \u0441\u0440\u0435\u0434\u0441\u0442\u0432\u0430] (Internet).\u00a0 http:\/\/rheumatologybg.org\/download\/consensus_3.doc . Accessed 14 Oct 2018"},{"key":"4202_CR21","unstructured":"NHIF requirements for the treatment of seropositive rheumatoid and psoriatic arthritis with disease-modifying antirheumatic drugs (DMARDs) in outpatient care [\u0418\u0437\u0438\u0441\u043a\u0432\u0430\u043d\u0438\u044f \u043d\u0430 \u041d\u0417\u041e\u041a \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0441\u0435\u0440\u043e\u043f\u043e\u0437\u0438\u0442\u0438\u0432\u0435\u043d \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u0435\u043d \u0438 \u043f\u0441\u043e\u0440\u0438\u0430\u0442\u0438\u0447\u0435\u043d \u0430\u0440\u0442\u0440\u0438\u0442 \u0441 \u0431\u043e\u043b\u0435\u0441\u0442-\u043c\u043e\u0434\u0438\u0444\u0438\u0446\u0438\u0440\u0430\u0449\u0438 \u0430\u043d\u0442\u0438\u0440\u0435\u0432\u043c\u0430\u0442\u0438\u0447\u043d\u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430 (\u0411\u041c\u0410\u0420\u041b) \u0432 \u0438\u0437\u0432\u044a\u043d\u0431\u043e\u043b\u043d\u0438\u0447\u043d\u0430\u0442\u0430 \u043f\u043e\u043c\u043e\u0449] (Internet). https:\/\/www.nhif.bg\/get_file?uuid=79d71f42-0189-4232-af78-97e0f2fd0dbb . Accessed 14 Oct 2018"},{"key":"4202_CR22","unstructured":"NHIF requirements for treatment of moderate to severe active seropositive rheumatoid arthritis, active juvenile arthritis, active and progressive psoriatic arthritis and severe active ankylosing spondylitis with disease-modifying antirheumatic drugs over 18 years of age in outpatient care [\u0418\u0437\u0438\u0441\u043a\u0432\u0430\u043d\u0438\u044f \u043d\u0430 \u041d\u0417\u041e\u041a \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0443\u043c\u0435\u0440\u0435\u043d \u0434\u043e \u0442\u0435\u0436\u044a\u043a \u0430\u043a\u0442\u0438\u0432\u0435\u043d \u0441\u0435\u0440\u043e\u043f\u043e\u0437\u0438\u0442\u0438\u0432\u0435\u043d \u0440\u0435\u0432\u043c\u0430\u0442\u043e\u0438\u0434\u0435\u043d \u0430\u0440\u0442\u0440\u0438\u0442, \u0430\u043a\u0442\u0438\u0432\u0435\u043d \u044e\u0432\u0435\u043d\u0438\u043b\u0435\u043d \u0430\u0440\u0442\u0440\u0438\u0442, \u0430\u043a\u0442\u0438\u0432\u0435\u043d \u0438 \u043f\u0440\u043e\u0433\u0440\u0435\u0441\u0438\u0440\u0430\u0449 \u043f\u0441\u043e\u0440\u0438\u0430\u0442\u0438\u0447\u0435\u043d \u0430\u0440\u0442\u0440\u0438\u0442 \u0438 \u0442\u0435\u0436\u044a\u043a \u0430\u043a\u0442\u0438\u0432\u0435\u043d \u0430\u043d\u043a\u0438\u043b\u043e\u0437\u0438\u0440\u0430\u0449 \u0441\u043f\u043e\u043d\u0434\u0438\u043b\u0438\u0442 \u0441 \u0430\u043d\u0442\u0438\u0440\u0435\u0432\u043c\u0430\u0442\u0438\u0447\u043d\u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u0438 \u043f\u0440\u043e\u0434\u0443\u043a\u0442\u0438 \u043d\u0430\u0434 18 \u0433\u043e\u0434\u0438\u0448\u043d\u0430 \u0432\u044a\u0437\u0440\u0430\u0441\u0442 \u0432 \u0438\u0437\u0432\u044a\u043d\u0431\u043e\u043b\u043d\u0438\u0447\u043d\u0430\u0442\u0430 \u043f\u043e\u043c\u043e\u0449] (Internet). https:\/\/www.nhif.bg\/get_file?uuid=74d9c325-9d5c-4494-bc53-68ddc9ccc955 . Accessed 14 Oct 2018"},{"key":"4202_CR23","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127\u20132137","journal-title":"Lancet"},{"issue":"1","key":"4202_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74(1):65\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203582","journal-title":"Ann Rheum Dis"},{"key":"4202_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the rheumatic diseases. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4202_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4202_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landew\u00e9 R, Van der Heijde D, Listing J, Brandt J, Braun JV, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M (2009) The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68(6):770\u2013776","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4202_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"MV Rudwaleit","year":"2011","unstructured":"Rudwaleit MV, Van Der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25\u201331","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4202_CR29","first-page":"593","volume":"67","author":"M Ivanova","year":"2014","unstructured":"Ivanova M, Manolova I, Goycheva P, Stoilov R (2014) Serum cytokines (TNF-alpha and IL-18) in ankylosing spondylitis in relation to disease activity. C R l\u2018Acad\u00e9mie Bulg Sci 67(4):593\u2013606","journal-title":"C R l\u2018Acad\u00e9mie Bulg Sci"},{"issue":"1","key":"4202_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Sch\u00f6ls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landew\u00e9 R, Mease P, Sieper J, Stamm T (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77(1):3\u201317","journal-title":"Ann Rheum Dis"},{"key":"4202_CR31","unstructured":"Bulgarian Rheumatology Society (2018) Consensus for the treatment of psoriatic arthritis [\u041a\u043e\u043d\u0441\u0435\u043d\u0441\u0443\u0441 \u0437\u0430 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u043f\u0441\u043e\u0440\u0438\u0430\u0442\u0438\u0447\u0435\u043d \u0430\u0440\u0442\u0440\u0438\u0442] (Internet).\u00a0 http:\/\/rheumatologybg.org\/download\/consensus_2.doc . Accessed 14 Oct 2018"},{"key":"4202_CR32","unstructured":"Bulgarian Rheumatology Society (2018) Consensus for the treatment of axial spondyloarthritis [\u041a\u043e\u043d\u0441\u0435\u043d\u0441\u0443\u0441 \u0437\u0430 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0430\u043a\u0441\u0438\u0430\u043b\u0435\u043d \u0441\u043f\u043e\u043d\u0434\u0438\u043b\u043e\u0430\u0440\u0442\u0440\u0438\u0442]\u00a0(Internet). http:\/\/rheumatologybg.org\/download\/consensus_1.doc . Accessed 14 Oct 2018"},{"issue":"Suppl 1","key":"4202_CR33","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/rmdopen-2015-000053","volume":"1","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Braun J (2015) Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open 1(Suppl 1):e000053. https:\/\/doi.org\/10.1136\/rmdopen-2015-000053","journal-title":"RMD Open"},{"key":"4202_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/rheumatology\/31.3.189","volume":"31","author":"TE McAlindon","year":"1992","unstructured":"McAlindon TE, Cooper C, Kirwan JR, Dieppe PA (1992) Knee pain and disability in the community. Br J Rheumatol 31:189\u2013192","journal-title":"Br J Rheumatol"},{"key":"4202_CR35","doi-asserted-by":"publisher","first-page":"d1165","DOI":"10.1136\/bmj.d1165","volume":"342","author":"E Nuesch","year":"2011","unstructured":"Nuesch E, Dieppe P, Reichenbach S et al (2011) All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 342:d1165","journal-title":"BMJ"},{"issue":"8","key":"4202_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7326\/0003-4819-133-8-200010170-00016","volume":"133","author":"DT Felson","year":"2000","unstructured":"Felson DT, Lawrence RC, Dieppe PA et al (2000) Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133(8):635\u2013646","journal-title":"Ann Intern Med"},{"key":"4202_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.16.4.494","volume":"16","author":"JH Kellgren","year":"1957","unstructured":"Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494\u2013502","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4202_CR38","first-page":"16","volume":"24","author":"T Georgiev","year":"2016","unstructured":"Georgiev T, Stoilov R, Penkov M, Ivanova M, Trifonov A (2016) Radiographic assessment of knee osteoarthritis. Revmatologiia (Bulgaria) 24(2):16\u201324","journal-title":"Revmatologiia (Bulgaria)"},{"key":"4202_CR39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/annrheumdis-2016-210815","volume":"76","author":"G Sakellariou","year":"2017","unstructured":"Sakellariou G, Conaghan PG, Zhang W et al (2017) EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann Rheum Dis 76:1484\u20131494. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210815","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4202_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.joca.2010.08.019","volume":"19","author":"VB Kraus","year":"2011","unstructured":"Kraus VB, Burnett B, Coindreau J et al (2011) Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartil 19(5):515\u2013542","journal-title":"Osteoarthritis Cartil"},{"issue":"5","key":"4202_CR41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00296-017-3887-y","volume":"38","author":"T Georgiev","year":"2018","unstructured":"Georgiev T, Ivanova M, Kopchev A, Velikova T, Miloshov A, Kurteva E, Yuzeir K, Penkov M, Kabakchieva P, Rashkov R, Stoilov R (2018) Cartilage oligomeric protein, matrix metalloproteinase-3, and Coll2-1 as serum biomarkers in knee osteoarthritis: a cross-sectional study. Rheumatol Int 38(5):821\u2013830","journal-title":"Rheumatol Int"},{"issue":"1","key":"4202_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/JSA.0000000000000182","volume":"26","author":"TM Simon","year":"2018","unstructured":"Simon TM, Jackson DW (2018) Articular cartilage: injury pathways and treatment options. Sports Med Arthrosc Rev 26(1):31\u201339","journal-title":"Sports Med Arthrosc Rev"},{"key":"4202_CR43","unstructured":"Bulgarian Rheumatology Society (2018) Consensus for the diagnosis and treatment of osteoarthritis [\u041a\u043e\u043d\u0441\u0435\u043d\u0441\u0443\u0441 \u0437\u0430 \u0434\u0438\u0430\u0433\u043d\u043e\u0437\u0430 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0430\u0440\u0442\u0440\u043e\u0437\u043d\u0430\u0442\u0430 \u0431\u043e\u043b\u0435\u0441\u0442]\u00a0(Internet).\u00a0 http:\/\/rheumatologybg.org\/download\/consensus_4.pdf . Accessed 14 Oct 2018"},{"key":"4202_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2014.01.004","volume":"48","author":"Y Cong","year":"2014","unstructured":"Cong Y, Gershwin EM, Chang C (2014) Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 48:10\u201313. https:\/\/doi.org\/10.1016\/j.jaut.2014.01.004","journal-title":"J Autoimmun"},{"issue":"1","key":"4202_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00296-010-1547-6","volume":"32","author":"LD Miteva","year":"2012","unstructured":"Miteva LD, Manolova IM, Ivanova MG, Rashkov RK, Stoilov RM, Gulubova MV, Stanilova SA (2012) Functional genetic polymorphisms in interleukin-12B gene in association with systemic lupus erythematosus. Rheumatol Int 32(1):53\u201359","journal-title":"Rheumatol Int"},{"issue":"8","key":"4202_CR46","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4202_CR47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/acr.23317","volume":"70","author":"SK Tedeschi","year":"2018","unstructured":"Tedeschi SK, Johnson SR, Boumpas D, Daikh D, D\u00f6rner T, Jayne D, Kamen D, Lerstr\u00f8m K, Mosca M, Ramsey-Goldman R, Sinnette C (2018) Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res 70(4):571\u2013581. https:\/\/doi.org\/10.1002\/acr.23317","journal-title":"Arthritis Care Res"},{"issue":"9","key":"4202_CR48","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725\u20131725","journal-title":"Arthritis Rheum"},{"key":"4202_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/rheumatology\/keu278","volume":"54","author":"AR Fonseca","year":"2015","unstructured":"Fonseca AR, Gaspar-Elsas MI, Land MG, de Oliveira SK (2015) Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology 54:241\u2013247","journal-title":"Rheumatology"},{"key":"4202_CR50","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771\u20131782. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201940","journal-title":"Ann Rheum Dis"},{"key":"4202_CR51","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/ard.2010.130476","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias GK, Ioannidis JPA, Aringer M et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074\u20132082. https:\/\/doi.org\/10.1136\/ard.2010.130476","journal-title":"Ann Rheum Dis"},{"key":"4202_CR52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies including therapeutics. Ann Rheum Dis 67:195\u2013205. https:\/\/doi.org\/10.1136\/ard.2007.070367","journal-title":"Ann Rheum Dis"},{"key":"4202_CR53","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1002\/art.24027","volume":"58","author":"S Muller","year":"2008","unstructured":"Muller S, Monneaux F, Schall N, Rashkov RK, Oparanov BA, Wiesel P, Geiger J, Zimmer R (2008) Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 58:3873\u20133883. https:\/\/doi.org\/10.1002\/art.24027","journal-title":"Arthritis Rheum"},{"key":"4202_CR54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4202_CR55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczy\u0144ski P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC et al (2017) Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol 69(2):362\u2013375","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4202_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0b013e328363eaa5","volume":"25","author":"CP Mavragani","year":"2013","unstructured":"Mavragani CP, Nezos A, Moutsopoulos HM (2013) New advances in the classification, pathogenesis and treatment of Sjogren\u2019s syndrome. Curr Opin Rheumatol 25(5):623\u2013629","journal-title":"Curr Opin Rheumatol"},{"key":"4202_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1741-7015-11-93","volume":"11","author":"A Tincani","year":"2013","unstructured":"Tincani A, Andreoli L, Cavazzana I, Doria A, Favero M, Fenini MG et al (2013) Novel aspects of Sj\u00f6gren\u2019s syndrome in 2012. BMC Med 11:93","journal-title":"BMC Med"},{"issue":"3","key":"4202_CR58","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","volume":"42","author":"FB Vivino","year":"2016","unstructured":"Vivino FB, Carsons SE, Foulks G, Daniels TE, Parke A, Brennan MT, Forstot SL, Scofield RH, Hammitt KM (2016) New treatment guidelines for Sj\u00f6gren\u2019s disease. Rheum Dis Clin 42(3):531\u2013551","journal-title":"Rheum Dis Clin"},{"key":"4202_CR59","first-page":"1165","volume-title":"Clinical features of systemic sclerosisRheumatology","author":"MB Bolster","year":"2015","unstructured":"Bolster MB, Silver RM (2015) Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS et al (eds) Rheumatology, 6th\u00a0edn. Mosby, St. Louis, pp\u00a01165\u20131176","edition":"6"},{"issue":"5","key":"4202_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","volume":"10","author":"J Wei","year":"2011","unstructured":"Wei J, Bhattacharyya S, Tourtellotte WG et al (2011) Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 10(5):267\u2013275","journal-title":"Autoimmun Rev"},{"key":"4202_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0049-0172(86)90040-5","volume":"16","author":"VK Rocco","year":"1986","unstructured":"Rocco VK, Hurd ER (1986) Scleroderma and scleroderma-like syndromes. Semin Arthritis Rheum 16:22","journal-title":"Semin Arthritis Rheum"},{"key":"4202_CR62","doi-asserted-by":"crossref","unstructured":"Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. In: Seminars in arthritis and rheumatism, 1 Feb 2008 (vol\u00a037, No. 4, pp.\u00a0223\u2013235). WB Saunders, Philadelphia","DOI":"10.1016\/j.semarthrit.2007.05.003"},{"issue":"11","key":"4202_CR63","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen Van Den","year":"2013","unstructured":"Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737\u20132747","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4202_CR64","first-page":"35","volume":"24","author":"E Krasimirova","year":"2016","unstructured":"Krasimirova E, Velikova T, Tumangelova-Yuzeir K, Ivanova-Todorova E, Kyurkchiev D, Kalinova D, Reshkova V, Kopchev A, Rashkov R (2016) A wide immunological profile in the diagnosis of progressive systemic sclerosis. Revmatologiia (Bulgaria) 24(2):35\u201351","journal-title":"Revmatologiia (Bulgaria)"},{"key":"4202_CR65","doi-asserted-by":"publisher","first-page":"e000260","DOI":"10.1136\/rmdopen-2016-000260","volume":"2","author":"Y Allanore","year":"2016","unstructured":"Allanore Y, Matucci-Cerinic M, Distler O (2016) Treatment of systemic sclerosis: is there any hope for the future? RMD Open 2:e000260. https:\/\/doi.org\/10.1136\/rmdopen-2016-000260","journal-title":"RMD Open"},{"key":"4202_CR66","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"4202_CR67","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC (1991) Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325(21):1487\u20131498. https:\/\/doi.org\/10.1056\/NEJM199111213252107","journal-title":"N Engl J Med"},{"issue":"9388","key":"4202_CR68","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dematomyositis. Lancet 362(9388):971\u2013982. https:\/\/doi.org\/10.1016\/S0140-6736(03)14368-1","journal-title":"Lancet"},{"issue":"4","key":"4202_CR69","first-page":"28","volume":"24","author":"D Kalinova","year":"2016","unstructured":"Kalinova D, Kopchev A, Nikolaeva S, Rashkov R (2016) Autoimmune myositis\u2014histological features in the skin and muscle biopsies. Revmatologiia (Bulgaria) 24(4):28\u201334","journal-title":"Revmatologiia (Bulgaria)"},{"key":"4202_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10354-017-0595-x","volume":"168","author":"LA Dourmishev","year":"2018","unstructured":"Dourmishev LA, Guleva DV, Miteva LG (2018) Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology. Wien Med Wochenschr 168:213. https:\/\/doi.org\/10.1007\/s10354-017-0595-x","journal-title":"Wien Med Wochenschr"},{"key":"4202_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"J Jennette","year":"2013","unstructured":"Jennette J, Falk R, Bacon P, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"4202_CR72","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.1780330811","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129\u20131134","journal-title":"Arthritis Rheum"},{"key":"4202_CR73","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122\u20131128","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4202_CR74","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1742-4801.2005.00103.x","volume":"2","author":"AL Dourmishev","year":"2005","unstructured":"Dourmishev AL, Serafimova DK, Vassileva SG, Dourmishev LA, Schwartz RA (2005) Segmental ulcerative vasculitis: a cutaneous manifestation of Takayasu\u2019s arteritis. Int Wound J 2(4):340\u2013345","journal-title":"Int Wound J"},{"issue":"2","key":"4202_CR75","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.crvasa.2017.06.002","volume":"60","author":"IS Petrov","year":"2018","unstructured":"Petrov IS et al (2018) Late outcomes after interventional treatment\u2014successful stenting of Takayasu arteritis lesions. Single center experience in Bulgaria. Cor Vasa 60(2):e114\u2013e121","journal-title":"Cor Vasa"},{"key":"4202_CR76","unstructured":"European Medicines Agency-Find medicine-RoActemra (Internet). http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000955\/human_med_001042.jsp&mid=WC0b01ac058001d124 . Accessed 25 July 2018"},{"key":"4202_CR77","unstructured":"US Food and Drug Administration (2017) FDA approves first drug to specifically treat giant cell arteritis (Internet). https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm559791.htm . Accessed 25 July 2018"},{"key":"4202_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225","journal-title":"Ann Rheum Dis"},{"key":"4202_CR79","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/945262","author":"NM Leonardo","year":"2015","unstructured":"Leonardo NM, McNeil J (2015) Beh\u00e7et\u2019s disease: is there geographical variation? A review far from the Silk Road. Int J Rheumatol. https:\/\/doi.org\/10.1155\/2015\/945262","journal-title":"Int J Rheumatol"},{"issue":"4","key":"4202_CR80","first-page":"31","volume":"23","author":"T Yoneva","year":"2015","unstructured":"Yoneva T, Rashkov R, Zdravkova Y (2015) Clinical and immunological analysis of the patients with ANCA associated vasculitides in the rheumatology clinic. Revmatologiia (Bulgaria) 23(4):31\u201347","journal-title":"Revmatologiia (Bulgaria)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4202-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4202-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4202-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T23:16:34Z","timestamp":1605395794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4202-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4202-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"16 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Tsvetoslav Georgiev declares that he has no conflict of interest. Rumen Stoilov declares that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}